CRISPR in Drug Discovery 2023

Presentation

Tue 7 February

8 February

[Schedule with Sessions only]

DAY 1

Auditorium

DAY 2

DAY 1

Auditorium

DAY 2

8:00

8:00:

8:05:

8:10:

8:15:

8:20:

8:25:

8:30:

Registration
08:30 (60 mins)

8:30:

8:35:

8:40:

8:45:

8:50:

8:55:

9:00

9:00:

9:05:

9:10:

9:15:

9:20:

9:25:

9:30:

Functional Genomics

Chairs: Andrew Bassett, Wellcome Sanger Institute

Conference and Session Welcome
09:30 (10 mins)
Andrew Bassett, Wellcome Sanger Institute

Target discovery by multimodal single cell CRISPR screens in primary immune cells
09:40 (30 mins)
Radu Rapiteanu, GSK

Single-cell CRISPR screens in primary human T cells identify regulators of Th2 cell skewing
10:10 (15 mins)
Henrik Schmidt — Myllia Biotechnology GmbH

CRISPR multiplexing for synthetic lethality and genetic modeling of polypharmacology
10:25 (30 mins)
Traver Hart, The University of Texas MD Anderson Cancer Center

9:30:

9:35:

9:40:

9:45:

9:50:

9:55:

10:00

10:05

10:10

10:15

10:20

10:25

10:30

10:35

10:40

10:45

10:50

10:55

Refreshment Break

10:55

11:00

11:05

11:10

11:15

11:20

11:25

11:30

Functional Genomics

Chairs: Andrew Bassett, Wellcome Sanger Institute

Single-Cell Cell Biology via Perturbation Profiling at Scale
11:30 (30 mins)
Paul Blainey, Broad Institute of MIT and Harvard and MIT Department of Biological Engineering

Improved methods for high-throughput knockout and knock-in screens in immortalized cell lines and iPSCs
12:00 (30 mins)
Ashley Jacobi — Integrated DNA Technologies

CRISPRi-based Functional Genetic Interaction Mapping in PD and FTD/ALS
12:30 (5 mins)
Stewart Humble, NINDS & University of Oxford

CRISPR-based Single cell approaches for mapping gene function and tumor evolution
12:35 (45 mins)
Jonathan Weisssman, Whitehead Institute

11:30

11:35

11:40

11:45

11:50

11:55

12:00

12:05

12:10

12:15

12:20

12:25

12:30

12:35

12:40

12:45

12:50

12:55

1:00

1:00:

1:05:

1:10:

1:15:

1:20:

Refreshment Break - Poster Session 13.30 - 14.00

1:20:

1:25:

1:30:

1:35:

1:40:

1:45:

1:50:

1:55:

2:00

2:00:

2:05:

2:10:

2:15:

2:20:

Functional Genomics

Chairs: Andrew Bassett, Wellcome Sanger Institute

In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer
14:20 (30 mins)
Dzana Dervovic, AstraZeneca

Accelerating Discovery and Manufacture of CRISPR-based Genome Editing Solutions
14:50 (5 mins)
Libby Naylor, GenScript Biotech

Full-genome isogenic/drug CRISPR screens identify novel genes involved in DNA replication, DNA repair, and sister chromatid cohesion
14:55 (10 mins)
Klaas de Lint, Amsterdam University Medical Center

Arrayed CRISPR screening in primary human Tregs using a multi-colour flow cytometry endpoint
15:05 (10 mins)
Charlie Dunlop, AstraZeneca Sofia Pavlou, AstraZeneca

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
15:15 (30 mins)
Robert Manguso, Massachusetts General Hospital Cancer Center

2:20:

2:25:

2:30:

2:35:

2:40:

2:45:

2:50:

2:55:

3:00

3:00:

3:05:

3:10:

3:15:

3:20:

3:25:

3:30:

3:35:

3:40:

3:45:

Refreshment Break

3:45:

3:50:

3:55:

4:00

4:00:

4:05:

4:10:

4:15:

Functional Genomics

Chairs: Andrew Bassett, Wellcome Sanger Institute

Transforming diagnostic confidence in genetic diseases using CRISPR-based variant effect assessment
16:15 (30 mins)
Hong Kee Tan, Wellcome Sanger Institute

The Joint AstraZeneca - Cancer Research Horizons Functional Genomics Centre: Using pooled CRISPR screening to drive oncology drug discovery
16:45 (5 mins)
David Walter, Cancer Research Horizons

CRISPR In Drug Discovery ... When CRISPR IS the Drug
16:50 (40 mins)
Fyodor Urnov, UC, Berkeley

4:15:

4:20:

4:25:

4:30:

4:35:

4:40:

4:45:

4:50:

4:55:

5:00

5:00:

5:05:

5:10:

5:15:

5:20:

5:25:

5:30:

Networking Event - Poster Session 18.00 - 18.30

5:30:

5:35:

5:40:

5:45:

5:50:

5:55:

6:00

6:00:

6:05:

6:10:

6:15:

6:20:

6:25:

6:30:

6:35:

6:40:

6:45:

6:50:

6:55:

7:00

7:00: